The drug has been approved to help treat type-2 diabetes, but a new study shows an increase in use in people with type-1 diabetes, and it may not be safe.

Pharma giant Novo Nordisk, which makes the obesity drug Wegovy, says the widespread availability of copycat medications is hurting its sales.

There’s no question about the popularity of GLP-1 weight loss drugs like Ozempic and Wegovy, but some doctors are worried the ...

OB-GYNs explain how they're using semaglutide and tirzepatide to treat symptoms of PCOS. The meds help treat weight gain, ...

The "Diabetes Monitoring, Treatment and Drug Delivery Market Size, Share & Trends Analysis | United States | 2025-2031 | MedSuite | Includes: Insulin & GLP-1, Continuous Glucose Monitoring and 7 more" ...

Studies show that high-protein diets can help GLP-1 (glucagon-like peptide 1) medication users be more successful in their ...

Also known as type 1.5 diabetes, here’s what to know about the onset, symptoms, diagnosis, and treatment options for latent ...

Mounjaro, a weight loss drug launched by Eli Lilly in India, could be a game-changer and has been making waves lately. Here's ...

With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...

Novo Nordisk will pay $200 million up front, with up to $1.8 billion in additional payments down the line, The Wall Street ...

The incidence and risk for suicidality and self-harm were low for individuals given glucagon-like peptide-1 receptor agonists ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...